Combination of CD20xCD3 Bispecific Antibodies with Ibrutinib and Lenalidomide Shows Efficacy in Relapsed/ Refractory CNS Lymphoma
Sandy Amorim(Hôpital Saint-Vincent-de-Paul), Laurent Pascal(Groupe Hospitalier de l'Institut Catholique de Lille), Bénédicte Hivert(Hôpital Saint-Vincent-de-Paul), Vincent Thibaud(Université Catholique de Lille), Emmanuelle Bourgeois Petit(Hôpital Saint-Vincent-de-Paul), Benjamin Carpentier, Alexandre Willaume(Périnatalité & Risques Toxiques)
Cited by 2
Related Papers
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|181
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
|Frontiers in Oncology|2019|80
Critical illness-associated cerebral microbleeds for patients with severe COVID-19: etiologic hypotheses
|Journal of Neurology|2020|55
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study
|Blood Advances|2021|51
A new role of glutathione peroxidase 4 during human erythroblast enucleation
|Blood Advances|2020|34